According to study findings presented during the 49th Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancers held in New Orleans March 24-27, clinical benefit has been found for women with recurrent ovarian cancer when using immune checkpoint inhibitors, but there was a higher rate of adverse events (AEs) than previously reported in other tumor types.
Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.
Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.
Adding an immunotherapeutic agent to chemotherapy had no impact on survival in patients with recurrent, platinum-resistant ovarian cancer, according to a late-breaking trial reported at the 2017 Society of Gynecologic Oncology Annual Meeting.
An immunotherapy targeting human papillomavirus-infected cells led to an unprecedented 1-year survival in patients with recurrent, metastatic cervical cancer, according to a phase II study reported at the 2017 Society of Gynecology Oncology Annual Meeting.
Maintenance chemotherapy failed to improve survival rates for women in complete remission from ovarian cancer after debulking surgery and adjuvant platinum-based chemotherapy, a large randomized trial showed.
Kathleen N. Moore, MD, discusses the use of PARP inhibitors such as niraparib for the treatment of ovarian cancer – advances that could be practice changing, she says.
A 7-transcript classifiers effectively predicted metastatic disease for patients with endometrioid endometrial cancer, with added promise shown when the gene expression signature was combined with pathologic features.
Mismatch repair–deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.
Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma. Across the world, many centers have shifted to more patients receiving neoadjuvant chemotherapy followed by surgery and further chemotherapy.
Results of a recent phase III trial suggested that the PARP inhibitor niraparib warrants consideration for patients with recurrent, platinum-sensitive, high-grade ovarian cancer, irrespective of <em>BRCA</em> status, a reviewer of the study concluded.
Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
Patients with ovarian cancer who were treated at the highest volume centers had superior overall survival but also higher readmission rates compared with lower volume hospitals, casting doubt on the value of this measure for patients with cancer.
Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against the human papillomavirus.
Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib, according to a subgroup analysis of the randomized ARIEL2 trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
<p>Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer. Neoadjuvant chemotherapy has been shown to decrease surgical morbidity, lowering the complication rates and risk of death. </p>
A new analysis of a randomized phase II trial showed PARP inhibitor rucaparib slowed progression of relapsed <em>BRCA</em>-mutant ovarian cancer regardless of whether the mutations were somatic or germline.
According to a recent study, lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists’ participation in global health activities.
In mid-December of 2014, the FDA approved the BRACAnalysis CDx diagnostic test to accompany the use of Lynparza (olaparib) in advanced ovarian cancer.
In a single-institution randomized prospective controlled trial of women with advanced epithelial ovarian cancer, 52.6% of patients in the PDS study arm had major complications with an MSKCC score of 3 or greater.
The angiogenesis inhibitor cediranib demonstrated acceptable activity and a tolerable safety profile as a monotherapy for patients with recurrent or persistent endometrial cancer.
Krishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.
The addition fosbretabulin tromethamine to bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in pretreated patients with recurrent ovarian cancer enrolled in the phase II GOG186i study.
Circulating tumor cells have previously been reported to be prognostic in other solid tumors: can they become a prognostic biomarker in cervical cancer?
A triage algorithm may identify patients with presumed advanced ovarian cancer who represent preoperatively defined candidates for diagnostic laparoscopy.
Barbara Ann Goff, MD, discusses an analysis looking at the care of ovarian cancer.
Two newly reported studies are providing more insight into the efficacy and safety profile of the PARP inhibitor olaparib in ovarian cancer.
Bradley J. Monk, MD, FACOG, FACS, on bevacizumab in combination with the vascular disrupting agent fosbretabulin for the treatment of patients with recurrent ovarian, tubal, or peritoneal carcinoma.
The addition of bevacizumab to a doublet chemotherapy regimen extended OS by nearly 5 months compared with standard chemotherapy alone in women with platinum-sensitive recurrent ovarian cancers.
A 2:1 open-label phase II trial of the FANG vaccine achieved a marked delay in time to progression, in all 14 of 21 patients with stage III/IV ovarian cancer who participated. The other 7 patients did not receive the vaccine.